Skip to main content
  1. Life
  2. Health & Fitness
  3. Healthcare

UCLA prostate cancer research benefits by addition of distinguished professor

See also

On May 6, UCLA Health System announced that internationally renowned urologic oncologist, Dr. Stuart Holden to its faculty as a health sciences clinical professor in the Department of Urology at the David Geffen School of Medicine at UCLA and associate director of the UCLA Institute of Urologic Oncology.

Dr. Holden has worked on the frontlines of prostate cancer for more than 36 years and has pioneered new treatments for urologic cancers. He will be working closely with Dr. Arie Belldegrun, professor of urology and director of the Institute of Urologic Oncology and will establish an executive urology program at UCLA. Dr. Holden’s dedication to patient care resulted in him being named medical director of the Prostate Cancer Foundation, which is the world’s largest prostate cancer research funding organization; he has held this position since the foundation’s inception in 1993.

“We are thrilled to have recruited Dr. Holden to join UCLA Urology,” noted Dr. Mark S. Litwin, professor and chair of the UCLA Department of Urology. He added, “For more than 50 years, our mission has been to deliver compassionate, high-quality patient care through innovative research and specialized urologic programs. It is an honor to have Dr. Holden fortify our team with his extensive urologic oncology expertise as we continue to improve urologic health care and work to heal humankind, one patient at a time.”

Dr. Holden introduced radioactive seed implantation to LA and was an early adopter of ultrasound-guided prostate biopsy. During his medical career, he has seen his advocacy of active surveillance, in which cancers are closely monitored with blood and other tests, become an established treatment option. At the Prostate Cancer Foundation, he has overseen funding for prostate cancer research become multi-disciplinary, inter-institutional and now global. Before joining the UCLA faculty. Dr. Holden was the director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center and the first holder of the Warschaw, Robertson, Law Families Chair in Prostate Cancer. In addition, he was a founding partner at Tower Urology in Los Angeles.

Dr. Holden explained, “UCLA urology has afforded me the opportunity to take on new challenges in my career. UCLA urology’s commitment to outstanding patient care and research in a collaborative environment at the Clark Urology Center and UCLA Institute of Urologic Oncology is well known throughout the world… I am looking forward to integrating oncology care with a multidisciplinary focus to help create groundbreaking results for the patients here at UCLA and beyond. In addition, I will have the privilege of joining with world-class colleagues as we teach and train future leaders in urologic oncology. This was an opportunity I just could not pass up.”

Dr. Holden completed his medical degree and received his surgical training at New York Hospital Cornell University Medical College. He completed his urology residency at Emory University and fellowships in urology and developmental genetics at Memorial-Sloan Kettering Cancer Center. He also was awarded a clinical fellowship from the American Cancer Society.